Biologics: Targets and Therapy is an international, peer-reviewed, open access journal patho-physiological rationale for, and clinical application of, biologic agents and their biosimilars in the management of autoimmune diseases, cancers, or other pathologies where a molecular target can be identified.
Biologics: Targets and Therapy will no longer consider meta-analyses for publication.
Specific topics covered by the journal include:
• Gene therapy
• Cell therapy
• Antibody-based therapy
• Blood components
• Vaccines
• Hormones
• Cytokines and growth factors
• Toxins
• Peptides
This journal is characterized by the rapid reporting of original research, reviews, basic science, clinical studies and commentaries.
The journal does not accept study protocols. The journal will consider case reports only if they make a valuable and original contribution to the literature.
When considering submission of a paper utilizing publicly available data, authors should ensure that such studies add significantly to the body of knowledge and that they are validated using the authors’ own data through replication in an original sample.
Editor-in-Chief:
Professor Shein-Chung Chow, Department of Biostatistics and Bioinformatics, Duke University School of Medicine, United States
Editorial Board:
Professor Melisa I. Barliana, Professor, Ph.D, Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.
Professor Melisa I. Barliana, Head of Master Program in Pharmacy, Head of Master Program in Clinical Pharmacy, Faculty of Pharmacy Universitas Padjadjaran Teaching Hospital Building, Indonesia
Dr Alida Benfante, Department of Pneumology, University Hospital Policlinico Paolo Giaccone, Italy
Dr William C. Cho, Queen Elizabeth Hospital, Hong Kong
Dr Wei-Qun Ding, Department of Pathology, University of Oklahoma Health Sciences Center, USA
Professor Robert Eisenberg, Department of Medicine, University of Pennsylvania, United States
Dr Bithiah Grace Jaganathan, Associate Dean, Students' Affairs, Professor, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, India
Dr Maher Kurdi, MD, FRCP (Canada), FRCPath, (UK), FEFN (EU), Clinical Associate Professor of Neuropathology and Neuromuscular Pathology. Chairman, Department of Pathology, Faculty of Medicine, Rabigh, King Abdulaziz University. Chief, Brain Tumour Research Group, King Fahad Medical Research Center, Kingdom of Saudi Arabia.
Professor Cato Laurencin, Albert and Wilda Van Dusen Distinguished Professor of Orthopaedic Surgery; Professor of Chemical and Biomolecular Engineering; Professor of Materials Science and Engineering; Professor of Biomedical Engineering; Chief Executive Officer, The Cato T. Laurencin Institute for Regenerative Engineering, The University of Connecticut, Storrs, CT, USA
Professor George Prendergast, George C Prendergast, Professor & President/CEO, Lankenau Institute for Medical Research, USA
Dr Ranjit Ranbhor, Scientific Advisor, Pergament & Cepeda LLP, New Jersey, USA
Professor Garry Walsh, School of Medicine, University of Aberdeen, United Kingdom
Professor Shuyu Zhang, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, China Mainland (PRC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![Bioanalysis Zone: Stay up to date with the hottest topics in the field of bioanalysis...]({"type":"image" , "src" : "/sda/112458/journalad-promotion-bioanalysis.png"})